CN103739669B - A kind of suppression interleukin-6 polypeptide and application thereof - Google Patents
A kind of suppression interleukin-6 polypeptide and application thereof Download PDFInfo
- Publication number
- CN103739669B CN103739669B CN201310748579.5A CN201310748579A CN103739669B CN 103739669 B CN103739669 B CN 103739669B CN 201310748579 A CN201310748579 A CN 201310748579A CN 103739669 B CN103739669 B CN 103739669B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- interleukin
- arthritis
- group
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 35
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 34
- 230000001629 suppression Effects 0.000 title abstract description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 10
- 229920001184 polypeptide Polymers 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 6
- 229940100601 interleukin-6 Drugs 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 206010003246 arthritis Diseases 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 101150101999 IL6 gene Proteins 0.000 description 7
- 210000003423 ankle Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 206010039361 Sacroiliitis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710115512 Nuclear receptor coactivator 5 Proteins 0.000 description 2
- 206010048873 Traumatic arthritis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PBQVHWFDMNCCIH-KNJAVFAGSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC PBQVHWFDMNCCIH-KNJAVFAGSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748579.5A CN103739669B (en) | 2013-12-31 | 2013-12-31 | A kind of suppression interleukin-6 polypeptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748579.5A CN103739669B (en) | 2013-12-31 | 2013-12-31 | A kind of suppression interleukin-6 polypeptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103739669A CN103739669A (en) | 2014-04-23 |
CN103739669B true CN103739669B (en) | 2015-08-26 |
Family
ID=50496753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310748579.5A Expired - Fee Related CN103739669B (en) | 2013-12-31 | 2013-12-31 | A kind of suppression interleukin-6 polypeptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103739669B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105085630A (en) * | 2015-08-31 | 2015-11-25 | 苏州普罗达生物科技有限公司 | Polypeptide for inhibiting mTOR and application thereof |
CN105061583A (en) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | Peripheral interleukin 35 polypeptide and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080969A1 (en) * | 2001-04-02 | 2002-10-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for infant chronic arthritis-relating diseases |
CN102417540A (en) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | Polyethylene glycol-modified integrin blocking agent HM-3 and application thereof |
CN102740888A (en) * | 2009-11-24 | 2012-10-17 | 奥尔德生物制药公司 | Antibodies to IL-6 and use there |
-
2013
- 2013-12-31 CN CN201310748579.5A patent/CN103739669B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080969A1 (en) * | 2001-04-02 | 2002-10-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for infant chronic arthritis-relating diseases |
CN102740888A (en) * | 2009-11-24 | 2012-10-17 | 奥尔德生物制药公司 | Antibodies to IL-6 and use there |
CN102417540A (en) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | Polyethylene glycol-modified integrin blocking agent HM-3 and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103739669A (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104127859B (en) | The application of polypeptide in preparation treatment or prevention medicine for treating rheumatoid arthritis | |
CN103739670A (en) | Polyethylene glycol modified polypeptide for inhibiting tumor necrosis factor-alpha and application of polypeptide | |
CN103739669B (en) | A kind of suppression interleukin-6 polypeptide and application thereof | |
CN103772489B (en) | Nf-KB peptide inhibitor 5 and application thereof | |
CN103772491B (en) | Nf-KB peptide inhibitor 3 and application thereof | |
CN103819540B (en) | Nf-KB peptide inhibitor and application thereof | |
CN103739671B (en) | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof | |
CN103254291B (en) | Tumor necrosis factor-alpha polypeptide inhibitors and application thereof | |
CN103285373A (en) | Preparation method and application of tumor necrosis factor (TNF)-alpha polypeptide inhibitor | |
CN103739673B (en) | A kind of polyethyleneglycol modified suppression interleukin-6 polypeptide and application thereof | |
CN103739677B (en) | A kind of suppression nuclear Factor-Kappa B polypeptide and application thereof | |
CN103772492B (en) | Nf-KB peptide inhibitor 4 and application thereof | |
CN103265619A (en) | Tumor necrosis factor-alpha polypeptide inhibitor and application thereof | |
CN105061583A (en) | Peripheral interleukin 35 polypeptide and application thereof | |
CN103288922A (en) | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof | |
CN103923180A (en) | Interleukin-6 polypeptide inhibitor and its application | |
CN103923185A (en) | Interleukin-6 polypeptide inhibitor and its application | |
CN103893161A (en) | Application of syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid) in preparation of medicine for preventing and treating rheumatoid arthritis | |
CN103923183A (en) | Interleukin-6 polypeptide inhibitor and its application | |
CN103923182A (en) | Interleukin-6 polypeptide inhibitor and its application | |
CN103288921A (en) | Polypeptide inhibitor of vascular endothelial growth factor 2 tyrosine kinase and application thereof | |
CN103751169A (en) | Application of 3'-methoxy benzyl-3,5-dimethoxy-4-(3'-methoxy benzyloxy)benzoate in preparation of drugs for treating or preventing rheumatoid arthritis | |
CN103751168A (en) | Application of 3'-methoxy benzyl-4-hydroxy-3,5-dimethoxy-benzoate in preparation of drugs for treating or preventing rheumatoid arthritis | |
CN110101845A (en) | Application of the irisin in the drug that preparation prevention and treatment Postoperative Cognitive Dysfunction and blood-brain barrier are damaged mediated encephalopathy | |
CN105504022A (en) | NF-kappa B polypeptide and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG YUANTAI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LUO RUIXUE Effective date: 20150720 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Yongjun Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LUO RUIXUE TO: XU YONGJUN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150720 Address after: 314000, room 8, building 778, 1205 Asia Pacific Road, Nanhu District, Jiaxing, Zhejiang, Jiaxing Applicant after: Yuan Tai bio tech ltd, Zhejiang Address before: 639 No. 211198 Jiangsu province Nanjing city Jiangning District University City longmian Road Applicant before: Luo Ruixue |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20171231 |